Stage 4 Prostate Cancer Has a Better Course Than Recurrent Disease

According to a new study, men with metastatic (stage 4) prostate cancer at diagnosis had, compared with men whose cancer was diagnosed at an earlier stage and after treatment recurred and became metastatic, a lower risk of death.
This may be because prostate cancers recurring after initial treatment tend to be more aggressive and have a different biology. The study in the journal Urologic Oncology was published on 8 August 2020.
Note: According to current knowledge, prominent factors associated with more aggressive prostate cancer biology include a large tumor diameter, a high Gleason score, high PSA and diagnosis at a young age.
- Related topic: What Is Prostate Cancer Risk Classification?
The study examined data from 14,753 patients diagnosed with prostate cancer between 1990 and 2016. Of these, 669 (5%) had metastatic disease:
- 303 (45%) had metastatic prostate cancer at diagnosis,
- while 366 (55%) had recurrence after initial treatment and progressed to metastatic disease.
Median follow-up was 40 months for men with metastatic prostate cancer at diagnosis and 22 months for those with recurrent metastatic disease. Among patients with metastatic disease at diagnosis, 21 (10%) initially received local treatment such as radiotherapy or surgery, and 272 (90%) initially received hormone therapy. Among patients who progressed to metastatic disease, 239 (65%) initially received local treatment and 127 (35%) initially received systemic hormonal therapy.
After adjusting the data for sociodemographic factors, year of diagnosis, comorbidities and marital status, the researchers reported a 34% lower risk of cancer-specific death in patients with metastatic disease at diagnosis than in those who progressed to metastatic disease. They found no difference in survival rates between men receiving combined local and hormonal treatment and those receiving local treatment alone.
These data suggest that local treatments will not benefit all patients with metastatic prostate cancer and that patients selected for local treatment within the metastatic group should be chosen carefully. They also support the need to identify patients with early-stage disease at diagnosis who have a high risk of recurrence.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.